KSC · 185750.KS
Chong Kun Dang Pharmaceutical Corp.
₩63,100+₩600 (+0.96%)
Chong Kun Dang Pharmaceutical Corp.’s quoted price sits in the lower half of its reported 52-week range, 35.68% below the high.
Loading market information…
KSC · 003090.KS · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Daewoong Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.62% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Daewoong Co., Ltd.’s forward annual dividend is ₩200 per share, paid annual. The forward yield is 1.32% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Daewoong Co., Ltd.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of ₩942. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Daewoong Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating alongside its various subsidiaries, Daewoong Co., Ltd. is primarily engaged in the production and sale of pharmaceutical products. Additionally, the company generates income from real estate leasing. Established in 1961, the firm transitioned its name from Daewoong Pharmaceutical Co., Ltd. to its current designation, Daewoong Co., Ltd., in 2002. Its corporate headquarters are located in Seongnam-si, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:38 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| ₩503.9B-1.89% vs estimate |
| Q3 2024 | Nov 14, 2024 | ₩1,088+155.2% vs estimate | ₩515.9B+1.32% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩63,100+₩600 (+0.96%)
Chong Kun Dang Pharmaceutical Corp.’s quoted price sits in the lower half of its reported 52-week range, 35.68% below the high.
₩86,900+₩600 (+0.7%)
Dong-A Socio Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.76% below the high.
₩3,965-₩35 (-0.88%)
JW Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 16.0% below the high.
₩16,910+₩60 (+0.36%)
Korea United Pharm Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.43% below the high.
₩931₩0 (0.0%)
Yungjin Pharm. Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 59.87% below the high.
₩35,600+₩200 (+0.56%)
Chong Kun Dang Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 35.97% below the high.
₩21,150-₩650 (-2.98%)
Ilsung Is Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.82% below the high.
₩24,750-₩250 (-1.0%)
Daihan Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.8% below the high.
